Related Experiment Video
Updated: Aug 29, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Efficient retroviral vector targeting of carcinoembryonic antigen-positive tumors
Simon Chowdhury1, Kerry A Chester, John Bridgewater
1Department of Immunology and Molecular Pathology, Windeyer Institute, London W1T 2AH, UK.
Abstract:
Many gene therapy approaches require specific, efficient gene delivery to cells in vivo. To target colorectal tumors we fused a single-chain variable fragment (scFv) directed against carcinoembryonic antigen (CEA) to the amphotropic murine leukemia virus envelope. A proline-rich hinge and matrix metalloprotease (MMP) cleavage site linked the two proteins. Following attachment to CEA, MMP cleavage of the envelope at the cell surface removed the scFv and proline-rich hinge, allowing transduction. This allowed selective targeting of CEA-positive cells in vivo after injection of producer cells at the site of the tumor, with up to 10% of cells within a CEA-positive tumor xenograft becoming transduced. Intraperitoneal injection of amphotropic producer cells resulted in transduction of cells in spleen, liver, and kidney, which was not detected when CEA-targeted producer cells were used. These results demonstrate the feasibility of using targeted retroviral vectors for in vivo gene delivery to tumors. Furthermore, the lack of transduction of host cells eliminates the risk of insertional mutagenesis leading to transformation of host hematopoietic cells.
Insights
This study developed targeted retroviral vectors for gene therapy. The novel vectors selectively deliver therapeutic genes to colorectal tumors expressing carcinoembryonic antigen (CEA), reducing off-target effects and insertional mutagenesis risks.
Area of Science:
- Biotechnology
- Molecular Biology
- Oncology
Background:
- Efficient in vivo gene delivery is crucial for gene therapy.
- Targeting specific cells, like colorectal tumors, remains a challenge.
Purpose of the Study:
- To develop a targeted retroviral vector system for selective gene delivery to colorectal tumors.
- To assess the efficacy and safety of CEA-targeted retroviral vectors in vivo.
Main Methods:
- Fused a single-chain variable fragment (scFv) against CEA to a murine leukemia virus envelope.
- Incorporated a matrix metalloprotease (MMP) cleavage site for regulated envelope shedding.
- Injected producer cells at tumor sites in xenograft models.
Main Results:
- Achieved selective targeting and transduction of CEA-positive tumor cells (up to 10%).
- Prevented transduction of spleen, liver, and kidney cells when using targeted vectors.
- Demonstrated reduced risk of insertional mutagenesis in host hematopoietic cells.
Conclusions:
- Targeted retroviral vectors show feasibility for in vivo tumor gene delivery.
- The system enhances safety by minimizing off-target transduction and insertional mutagenesis.
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Mechanisms of Retrovirus-induced Cancers

